State Street SPDR S&P Biotech ETF XBI
157.60 USD +2.63 (+1.69%)
Nov 4, 2026, 2:24 PM EST
152.65 Day range 158.35
108.04 52-week range 169.55
- YTD
- +29.25%
- 1 year
- +45.87%
- Market cap
- 8.10B
- YTD return
- +29.25%
- 1-year return
- +45.87%
- Volume
- 7.43M
- Avg volume
- 8.92M
- Open
- 158.35
- Previous close
- 154.97
- Day's range
- 152.65 – 158.35
- 52-week range
- 108.04 – 169.55
5m -1.74 (-1.09%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 156.33
- 200-day average
- 141.78
Next earnings
Consensus EPS estimate 0.00.
About State Street SPDR S&P Biotech ETF
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
News
Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge 
Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs 
ETFs That You May Consider Amid a Strengthening Biotech Outlook 
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? 
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? 
Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million 
SPDR S&P Biotech ETF $XBI Stock Sold by Banque Pictet & Cie SA 
Traders Purchase Large Volume of Call Options on SPDR S&P Biotech ETF (NYSEARCA:XBI) 
From Laggard to Leader: The Surprising Comeback of Healthcare 
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Your note
Sign in to keep a note on XBI — it syncs with the Stock Master app.